Profile
Pascal Lemaire has held director positions at Symphogen A, Servier Canada, Inc., and GeNeuro SA (Switzerland).
Pascal Lemaire active positions
| Companies | Position | Start |
|---|---|---|
| GENEURO SA | Director/Board Member | 2024-03-17 |
Servier Canada, Inc.
 Servier Canada, Inc. Pharmaceuticals: MajorHealth Technology Servier Canada, Inc. provides healthcare services. It manufactures pharmaceuticals for cardiology, diabetes, depression, venous disease and menopause. The company was founded in 1978 and is headquartered in Quebec, Canada. | Director/Board Member | - |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GENEURO SA | Health Technology |
| Private companies | 2 |
|---|---|
Servier Canada, Inc.
Servier Canada, Inc. Pharmaceuticals: MajorHealth Technology Servier Canada, Inc. provides healthcare services. It manufactures pharmaceuticals for cardiology, diabetes, depression, venous disease and menopause. The company was founded in 1978 and is headquartered in Quebec, Canada. | Health Technology |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
- Stock Market
- Insiders
- Pascal Lemaire
